Status:
COMPLETED
Rifaximin for Prevention of Travellers' Diarrhea
Lead Sponsor:
Bausch Health Americas, Inc.
Conditions:
Diarrhea
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo...
Detailed Description
To determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
Eligibility Criteria
Inclusion
- travelling to Mexico within 72 hours of enrollment
- read and understand English
- in good health
Exclusion
- acute diarrhea within previous 7 days
- taken FQs (any drug in this class), macrolide, azalide, or trimethoprim-sulfamethoxazole within 7 days or enrollment or anytime during study.
- taken antidiarrheal medication within 24 hours of enrollment or anytime during study.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT00742469
Start Date
June 1 2005
End Date
April 1 2007
Last Update
December 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of San Diego
Guadalajara, Jalisco, Mexico, 45090